Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,157 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Imaging Agent Clear all
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Not applicable Interventional

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

NCT04769310
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic
Interventions
Cardiac and Brain MRI
Device
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115
View directory record Official record
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 2, 2026, 4:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610
View directory record Official record
Conditions
Solid Tumor
Interventions
68Ga-FAP-2286, 177Lu-FAP-2286
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

NCT02400359
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Lorcaserin HCl, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Not yet recruiting Not applicable Interventional

Hypoxia-targeted Radiotherapy Boost for GBM

NCT07769918
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Dynamic susceptibility contrast MRI (DSC-MRI), Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps, Varian TrueBeam
Device · Other · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)

NCT00707876
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
ferumoxytol
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 2, 2026, 4:39 PM EDT
Recruiting Not applicable Interventional

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT05977036
View directory record Official record
Conditions
Metastatic Breast Cancer, Unresectable Breast Cancer
Interventions
DiviTum® TKa assay, CDK4/6 + Endocrine therapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Early Phase 1 Interventional

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

NCT03154411
View directory record Official record
Conditions
Primary Soft-tissue Sarcoma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 2, 2026, 4:39 PM EDT
Not listed Not applicable Interventional

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 2 Interventional Results available

Intraoperative Detection of Residual Cancer in Breast Cancer

NCT03321929
View directory record Official record
Conditions
Breast Cancer
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 2, 2026, 4:39 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults

NCT02354807
View directory record Official record
Conditions
Brown Fat
Interventions
Mirabegron, Cold exposure
Drug · Other
Lead sponsor
Otto Muzik
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 2, 2026, 4:39 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Recruiting Phase 3 Interventional

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Procedure · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Not applicable Interventional Results available

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

NCT04870645
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Advanced Magnetic Resonance Imaging, Conventional Magnetic Resonance Imaging, Gadolinium-Chelate, Iopamidol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 2, 2026, 4:39 PM EDT
Withdrawn Not applicable Interventional

Ventricular Arrhythmia Ablation With the Use of Non-Invasive ECG Imaging Technology

NCT04219501
View directory record Official record
Conditions
Premature Ventricular Contraction, Ventricular Tachycardia
Interventions
VIVO
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence

NCT01468012
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa carbidopa and entacapone (LCE), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

NCT01295931
View directory record Official record
Conditions
Melanoma
Interventions
Indocyanine Green (IC-Green), Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Early Phase 1 Interventional

Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954
View directory record Official record
Conditions
Normal Physiology, Opioid Use Disorders
Interventions
[11C]raclopride plus placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preliminary Effect of Food Processing and Sweeteners on Glycemic and Metabolic Measures

NCT05658757
View directory record Official record
Conditions
Blood Sugar; High, Blood Pressure, Dietary Habits
Interventions
Regular sweetened commercial foods, Allulose sweetened commercial foods, Whole and minimally processed and sweetened foods
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
20 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 2, 2026, 4:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 4:39 PM EDT
Recruiting Phase 3 Interventional

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553
View directory record Official record
Conditions
Metastatic Colon Cancer, Stage III Colon Cancer
Interventions
FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 2, 2026, 4:39 PM EDT
Recruiting Early Phase 1 Interventional

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

NCT07278986
View directory record Official record
Conditions
Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies
Interventions
CYTALUX™ (pafolacianine), 1788 4K Camera System with Advanced Imaging Modality
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 2, 2026, 4:39 PM EDT